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ABSTRACT 
The control of prolactin secretion is a complex interaction of 
peptides and neurotransmitters acting either in an inhibitory or 
stimulating way to effect final secretion of this hormone from the 
lactotrope cell in the anterior hypothalamus. These factors may act 
either directly on the lactotrope cell or indirectly by changing 
either dopamine restraint of prolactin secretion or by modulating 
peptide substances or neurotransmitters higher up in the 
hypothalamus. Gonadal steriods may also modulate 
peptides or dopamine at the level of the lactotrope. 
the effect of 
Prolactin's major role in the female rat is one of milk production 
post - partum, nurturing the young. It probably also has other 
physiological functions and may play a part in the menstrual cycle 
although this is controversial. 1 Certainly pulsatile secretion of 
prolactin during the menstrual cycle is well established 3 & • and in 
~ 
the luteal phase this is concommitant with the secretion of 
luteinizing hormone. 
Theories explaining the synchronous surges seen during this phase of 
the menstrual cycle have been proposed and GnRH has been implicated 
in the genesis of the concordance of these secretory spikes.• 
Using a potent GnRH antagonist an experiment was undertaken to 
establish the role of GnRH by blocking this hypothalamic peptide and 
observing the effect that this had on luteinizing hormone, prolactin 
and follicle stimulating hormone. In the first part of the thesis 
the control of prolactin secretion is reviewed. In the following 
section, an experiment was performed using a potent GnRH antagonist. 
A dose response curve was established for the antagonist action on 
LH. Then a twice maximum dose of this peptide was administered to 
three subjects in the midluteal phase of the menstrual cycle and the 
response of LH, prolactin and FSH was measured. The results indicate 
that although the GnRH antagonist significantly blocked LH secretory 
peaks,' this action was not observed for either prolactin or FSH. 
This result is perhaps at variance with previous data which 
suggested that GnRH was responsible . for concordant secretory spikes 
of LH and prolactin in the midluteal phase of the menstrual cycle. 
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REVIEW OF PROLACTIN SECRETION 
Introduction: 
Prolactins, somatotrophins and placental lactogens form a group of 
protein hormones characterised by a high degree of homology in their 
Amino Acid sequence. There is evidence that this group of 
biologically related proteins has arisen from a shorter primordial 
peptide by intragenic duplication preceding extragenic duplication. 
Prolactin is less related to growth hormone than to placental 
lactogen. This evolution of the two separate hormones produced by 
extragenic duplication probably occurred early on before the 
evolution of lactation as the pituitaries of birds, reptiles and 
amphibians seem to contain separate prolactin-like and 
somatotrophin-like hormones. However, prolactin could conceivably 
have been a growth promoting substance and may have promoted growth 
in lower vertebrates including some teleost fishes and reptiles. 6 
The early anterior pituitary hormones with the exception of 
prolactin were committed early on in vertebrae phylogeny to the 
control of a single or, at most, a few physiological processes. 
Prolactin differed from these other hormones in controlling a wide 
variety of different physiological mechanisms which varied according 
to the species in which the action of this versatile hormone was 
-man i fest 8 , 7 
Thus, in fish prolactin is concerned with the regulation of water 
and electrolyte metabolism 6 • 8 " 7 
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In amphibians, for examp l e, urodeles (particularly when they are 
a quatic), prolactin may have osmotic regulating and growth promoting 
f unctions. It has even been suggested that these effects may be 
important ontogenetically in mammals i.e. in foetuses and neonates.• 
In some eutheria, for example the rat, prolactin maintains the 
corpus luteum, while in other species evidence is scant but would 
suggest that a similar situation may apply, 
levels of prolactin are necessary. 1 
although only minimal 
Other actions of prolactin include effects on parental behaviour, 
v arious metabolic effects in birds, amphibians and mammals, effects 
on the rat testis, and female amphibian reproductive tract, and an 
antigonadotrophic effect in nonmammalian species; 
\ 
in birds the 
formation of crop "milk", release of "milk" production and the brood 
patch ; and probably its most important function, that of nurturing 
the young and the production, in mammals, of milk . 0 What has brought 
about the change of function of prolactin through evolution in these 
different species is perhaps uncertain but it seems likely to have 
been a change in the target cells. 6 
Four diffe rent molecular variants of prolactin are found on gel 
electrophore s is and these have been named according to their 
s edimentation rates. 9 A s pecifi c variant may be secreted under 
ce rtain situations and may give rise to a specific physiological 
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ElC t j u n. 1 0 & I I 
In pathological states particular forms of prolactin are secreted 12 • 
13 • 1 1 and this preferential release of one or other form(s) is 
found in situations contrasted by high or low secretory rates, 11 
14 and after stimulation with Thyrotrophic Hormone. 11 • 14 
• 
Not only may prolactin exist in different forms, but lactotroph 
cells in the pituitary gland are heterogenous in morphology and 
function 10 and immunocytochemistry has distinguished four different 
types of cells distinguished by the contour of the cell and the size 
and shape of the secretary granules in rats. 16 
At present the possible relationship betw~en the molecular diversity 
of prolactin and the cellular diversity of ~the 
. 
lactotrophs is 
speculative. 10 
It is possible that most prolactin in the resting state in normal 
people circulates as "Big-Big" prolactin which is biologically less 
active than e.g. "small" prolactin. 11 , 
·A circadian rhythm exists both in the male rat and in the human 
which is abolished by drugs which block 5-HT. 18 The basal secretion 
of the gonadotrophins and _prolactin is pulsatile and in the former 
this is thought to reflect the importance of frequency modulation of 
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gonadal function by the brain-pituitary system, 20 seen most 
convincingly in seasonal breeders. 13 
The pulse.tile pattern of tonic prolactin release has been recognized 
for some time. 17 • 3 • 1 • The Nycthemeral maximum occurs in late 
sleep u~der normal conditions of health and this pattern is absent 
in the last trimester of pregnancy and in some pathalogical states 
and may be related to either pulsatile GnRH secretion or to another 
mechanism which originates within the pituitary. 10 • 1 II 
To s upport the view that GnRH is responsible for prolactin 
pulsatility is the observation that synchrony exists between 
prolactin and LH in the luteal phase ~f the menstrual cycle• and in 
sleep associated peaks of LH during puberty. 20 
Although the lactotroph and . gonadotroph ce?ls may communicate 
information via intercellular gap junctions or in a paracrine 
fashion, 10 and although a common neuronal pathway may account for 
GnRH and prolactin pulsatility, the role of GnRH directly 
influencing tuberoinfundibular dopamine (TIDA) neurons was thought 
to be one of the more attractive theories to explain these 
observations (of LH and prolactin synchrony).• 
Prolactin inhibiting factors: 
Everett 21 in 1954, first reported that prolactin secretion was 
s timulated by the transplantation of the pituitary gland beneath the 
kidney capsule, and seven years after, in the early 1960's, it 
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became apparent that the hypothalamu s in some way, inhibited 
prolactin secretion in vitro . 22 More work and cogent observation 
o ver the next ten years consolidated this finding 22 but the factors 
responsible for inhibition of prolactin by or from the hypothalamus 
remained obscure. 22 • 2 3 
It became apparent that monoamines had an important role in some or 
other ' way in this control although the mechanism appeared obscure.a• 
Anatomical data had shown that tuberoinfundibular dopaminergic 
nuerons terminated in the median eminence, adjacent to portal blood 
ve s se ls leading to the anterior pituitary and that other 
dopamine rgic n e urons originating in the arcuate nucleus terminated 
i n t he neuro i ntermediate lobe of the pituitary gland. 2 6 
I t wa s al so known that catecholamines were present in the 
hypothalamus in relatively high concentrations ~but the significance 
of this was uncertain. 24 However, Bridge et al in 1970 showed that 
c atecholamines inhibited prolactin secretion in isolated rat 
pituitary glands. This was also shown by other workers. 24 Dopamine 
was thought of as the main PIF but the site of action was 
c ontroversial. 22 • a a In vivo studies 26 showed that dopamine 
inhibited prolactin secretion. Although it also inhibited prolactin 
when injected i nto a single portal vessel, 37 evidence that in vivo 
. dopam i n e inhib i t e d prolactin at th e pituitary wa s lacking, 
especially a s some in vivo studies had s hown that do p amine seemed to 
act o n the hypo thalamus to release PIF . 2 8 
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Because dopamine receptors we re found in the pituitary gland but 
we re absent in the hypothalamus, Brown et al cont e nd e d that dopamine 
acted directly on the pituitary as an inhibiting factor rather than 
indirectly on the hypothalamus. 29 These receptors were found, not 
only on pituitary membranes but also, specifically, on 
lactotrophs. 30 Dopamine was also found in hypophysial stalk plasma 31 
• 
9 in amounts sufficient to inhibit prolactin release. 32 
A major breakthrough occurred when more accurate and sophisticated 
ways were found of measuring dopamine in stalk blood using liquid 
chromatography coupled with an electrochemical detector system 31 and 
b y radioenz ymati c assay techniques. 9 
S ince the ini t ial investigations of the 1960's and 70 's , many other 
s tudie s h a v e n o w shown that dopamine has an important role in 
inhibiting prolactin secretion. 8 • 10 , 33 • 3 4 • 23 Inhibition occurs 
via speci f i c D2 dopamin e receptors which are negat i vely linked to 
\ 
adenylate cyc lase ie. DA reduces adeny late cyclase activity and 
inhibits cAMP accumulation. 35 , 3 8 • 37 
Other mechan i sms invoked at a subcellular level to explain DA effect 
on the lactrotroph include modulation of the electrical activity of 
the cells through an interaction of DA with a "receptor-potassium 
channel" complex located in the cytoplasmic membrane and, by a 
change of c a++ flux . Thi s mechanism may operate by maintaining a 
high (Ca+l) when DA is absent and the voltage dependent Ca••channels 
are maxima l ly activated; DA, by causing hyperpolar i zation of the 
membrane , ma y inactivate the membrane ca++ channels which, in 
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turn, lead to a decrease 
prolactin release. 38 
in the cytosolic Ca++ thus 
Anatomy of the Tuberoinfundibular Dopaminergic System 
inhibiting 
There are two major DA pathways from the hypothalamus to the 
pituitar~ gland. These are the incertohypothalamic and the (TIDA) 
pathways. 38 There are also projections from the periventricular DA 
system. 38 It is the TIDA system, however, which is directly involved 
in prolactin secretion. The perikarya of these TIDA neurons are 
located in the arcuate and periventricular nuclei of the medial 
basal hypothalamus and are further subdivided into two groups: the 
TIDA neurons itself, with terminals in the median eminence and the 
pituitary stalk, and the tuberohypophyslal neurons, with terminals 
in the n~ural and the intermediate lobes of the pituitary. 38 
DA axon terminals are especJally abundant id the median eminence 
where they are found close 
terminals, apendymal cells 
in proximity to other monoaminergic 
and precapillary spaces of the portal 
vessels. 88 DA projections to the intermediate and neural lobes 
originate from the anterior and central portions of the arcuate 
nucleus, respectively. 83 TIDA neurons lack a high affinity transport 
system for DA and thus more of this monoamine is available for 
transport by the blood away from the terminals. 40 
There is considerable diversity within the TIDA system and this has 
been well reviewed by Ben~Jonathan. 38 The implication of this is 
thal axon terminals of the two TIDA branches (to the posterior lobe 
PAGE 7 
and to the median eminence) may have different susceptibilities to 
extrinsic modulating influences or to genetic defects. 
Blood flow within the hypothalamo-hypophysial vessels: 
DA is transported along a capillary network called the hypophysial 
portal capillaries in the median eminence, pituitary stalk and 
neural lobe which connects the hypothalamus and the pituitary gland . 
These capillaries are supplied by the superior, middle and inferior 
hypophysial arteries. Blood is able to flow both antegrade and 
retrograde, depending on the state of vasoconstriction in these 
vessels. Substances can thus be transported from the hypothalamus 
and posterior pituitary and vise-versa. 13 
DA secreted into the portal blood is derived primarily from a newly 
synthesized pool rather than from a storage pool and depends upon 
intact hypothalamic 
of Dopamine 
storage and monoamine oxidase activity. 41 The 
. 
control synthesis itself may possibly influence 
prolactin secretion. In rats it has been shown that a reduced PTERIN 
cofactor ( BH4) is necessary along with tyrosine and Oz for the 
synthesis of DA, and the administration of increases DA 
synthesis in the striatum. 42 • 43 
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Other Inhibiting Factors 
Although DA is the main inhibitory substance operating on the 
lactotrophs, it seems it is not the only one because the amount of 
this catecholamine in the hypophysial blood, significantly reduces 
the amount of prolactin but does not completely supress its 
secretion. 10 
It is ·also possible that Dopamine tonically stimulates the secretion 
of another factor, PIF. 32 .. 2 2 
Another reason to postulate some other inhibitory factor is that 
there is a discrepancy in the amount of Dopamine in the hypophysial 
stalk plasma necessary to inhibit prolactin in male rats as compared 
to female rats. 10 Although a second source of DA may be contributed 
to by the posterior pituitary, 33 this contribution is probably very 
small . 7 
DA and prolactin are both involved in an interplay with other 
releasing and/or modulating hormones and neurotransmitters . 3 a 
Factors affecting DA action on Pr~lactin and other 
factors influencing Prolactin secretion. 
1) Neuropeptides and Neurotransmitters: Because of 
inhibitory 
reservations 
.expressed above that DA was the only PIF, the search continued for 
other neurotransmitters and neuropeptides which may 
pro l act in r elease . Although it now appea r s that GABA 10 , a. 
influence 
38 the TRH 
metabolite histadyl-proline diketopiperazine 44 " 45 and the catechol 
oes tr ogen 2 - hydroxyestradiol 46 all inhibit prolactin, i t is unlikely 
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t hat any are tonic inhibitors of spontaneous prolactin release. 10 
However, GABA may play a role in regulating prolactin and LH surges. 
Employing a push-pull cannula 47 it has been shown that mechanisms 
regulating prolactin and luteinizing hormone surges reside in the 
MPO/AH and this may be causally related to and modified by Estradiol 
(Ez) secretion, which, in turn, may be related to GABA release. GABA 
may also inhibit the release of either another nondopaminergic PIF, 
or a substance which tonically inhibits the release of a PRF. 47 
GABA has a dual effect on prolactin secretion, one component of this 
GABAergic pathway exerts a stimulatory effect on prolactin via 
inhibition of TIDA neuron function and an inhibitory component 
probably acts via specific GABAergic receptors. 48 • 4 8 
The most important nondopaminergic factor inhibiting prolactin 
release appears to be secreteq as a GnRH 60 associated peptide (GAP) 
recently isolated by Seeberg et al using genetic recombination 
techniques to synthesize the fragment which is part of the GnRH 
precursor and is separated from the GnRH peptide by 3 amino-acids 
(GlyLys Arg) . 42 • 43 It is found in · hypothalamic neurons coexisting 
with GnRH 50 and both GnRH and GAP are . secreted in situations where 
there is an inverse relationship between prolactin and gonadotrophin 
secretion and where 
·for this. 43 
Converse l y, reduced (or 
it has been invoked as a possible explanation 
absent) GnRH and GAP release into the 
hypophysial portal vessels would lead to high prolactin and low 
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gonadotrophin concentrations in plasma . 42 
The conclusions postulated about GAP have been critisized for a 
number of r easons 42 but further research will undoubt e dly clarify 
this issue in due course. 
Other neurotransmitters and peptides which have been postulated to 
inhibit prolactin release from the pituitary include 
noradrenalin , 16 • 6 1 & 6 Z acetylcholine 34 • 6 a , 1 6 , 1 0 • 6 1 and 
prolactin itself. 10 , 33 • 6 4 • 6 a 
Histamine seems to have a dual action on prolactin secretion, 
depending on which receptors, Hl or H2, are operative. 66 • 6 II • 1 e 
The form e r stimulates prolactin secretion, perhaps via an 
interact ion 
i nh ibit ion 
with TIDA neurons, 66 while the latter re s ults in 
of prolactin sec.ration, possibl~ mediated via nor 
adrenalin. 67 
The effect of noradrenalin seems less consistent than that of DA and 
its physiological role is uncertain. 16 
This action is probably very complicated as has been highlighted in 
in-vivo experimentation utilizing 
· i ntrapituitar y perfusion studies using 
measuring ca te c holamines (and othe r 
intrahypothalamic and 
and a push- pull cannula 
neuropeptides) dra i ning the 
median em i n ence through portal vessels to the pituitary. 47 
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Noradrenalin turnover in different parts of the hypothalamus may 
differ because the projections of the NE axon terminals are diffuse 
with little or no topographical orientation. 47 Thus the effect of 
the catecholamine may even differ in opposing directions ie. 
stimulating or inhibitory, depending on different structures within 
the hypothalamus. 47 Modulation by estradiol receptors or receptive 
neurons may also determine nor adrenalin action. DA itself probably 
acts ·on NE release indirectly in the MBH, disinhibiting its release 
in male rats. 47 
Acetylcholine (AcCh) probably inhibits phasic or induced secretion 
of prolactin 34 Evidence for this is that when the acetylcholine 
content in the central nervous system, is increased by 
physostigmine, prolactin decreases. 68 However, cholinergic agonists 
or antagonists probably do not affect basal prolactin levels. 68 
Muscarinic and nicotinic antagonists block oestrogen induced 
' 
prolactin release. 34 In other conditions stimulation of nicotinic 
and muscarinic receptors may give opposite actions 68 and some of 
these actions may be dependent on the dose of the respective 
neurotransmitters. 34 
Prolactin itself has a negative feedback on its own secretion. 10 , 
3 a , 6 4 , 60, 8 1 I, 63 by causing an increase in the rate of DA 
_synthesis and turnover in the TIDA nerve terminals in the median 
eminence after a delay of 12 - 16 hours. 61 This action of prolactin 
requires protein synthesis as it is blocked by pretreatment with 
cycloheximide and thus it has been thought that its action on TIDA 
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neurons may either be a direct one or an indirect action altering 
the activity of afferent neuronal systems projecting onto the TIDA 
neurons. 61 
Thi s short feedback loop of prolactin on the TIDA or other neuronal 
networks is probably the most important feedback mechanism of 
prolactin as no identifiable target organ hormone(s) have been 
isolated. 83 Two possible interdependent components of prolactin 
action exist. 61 The first is a ra~id tonic component which mediates 
short term changes in TIDA neuronal activity in response to acute 
changes in circulating prolactin. The second component is the 
induction of a delayed component, which responds to prolonged 
increases in plasma Prolactin and modifies the capacity of the tonic 
c omponent. 61 
The physiological significance of this may ~ be to prevent rapid 
depletion of anterior hypothalamic prolactin stores by acute stimuli 
to prolactin release eg. suckling where within minutes the prolactin 
concentration in the blood may rise ten fold. 64 
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Prolactin Releasing Substances 
There has been a profusion of substances reported as stimulatin
g 
prolactin release by direct stimulation of the pituitary 
lactotrophs , the most important of which is TRH which will be 
discu s sed below (see page 17) with suckling. It has b ee n pointed out 
however, that the capacity of any one of these peptides to cause th
e 
release of prolactin, does not necessarily mean that they a
re 
releasing hormones in the physiological sense, even though some h
ave 
been measured in hypophysial stalk plasma.
10 Experimental design has 
focussed on prolactin release in vitro but · this has limite
d 
verification in the in vivo situation after dopamine restraint.
47 
These substan c es include VIP, 112 • 119 , 114 • 116, 
6 II , Pt II 7 serotonin, 118 
neurotensin , t1° bombesin, 70 
substance p, 6 0 epidermal 
estradiol, 74 and GnRH, 4 & 
leu - encephalin, 77 
The endogenous opioids, the 
angiotensin I I • 7 i vasopressin, 72 
growth factor, 73 cholecystokinin, 112 
7 6 B- endorphan, .76 met enkephalin, 78 and 
~ 
endorphans and the enkephalins, may 
increase prolactin secretion not only by a decrease in the r
elease 
and synthesis of DA, but also by increasing the uptake 
TIDA neurons, thereby decreasing the availability 
of 
of 
transport via portal vessels to the anterior pituitary .
3 3 .. 
DA 
DA 
7 • 
into 
for 
The main action of the opioids on prolactin secreti o n is directed 
at 
the hypothalamus, but whether they modif y prolactin release under 
normal conditions or only in the stress related rise in prolac
tin, 
is uncertain . However, it seems possibl e /likely, that the stress 
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related r ise in prolactin which overcomes normal DA inhibition, may 
also be related to an opioid related release of prolactin- releastng 
hormone. 33 Both_}( - and k - opiate receptors mediate the 
prolactin. 78 
Factor s whi c h modify Prolactin release 
The action of ovarian steroids on Prolactin release: 
increases in 
Altho~gh ovarian steroids modify prolactin release, the exact 
mechanisms remain controversial 88 mainly due to the fact that these 
steroids have an intergrated action on brain and pituitary, and 
prevent a clear distinction between primary and secondary effects. 
Secondly, they regulate the secretion of other reproductive hormones 
(e.g . GnRH) which may influence prolac tin secretion indirectly. 
Estrogens (Ea) and progesterone have synergistic or antagonistic 
actions dep e nding on their relative concentrations in plasma and on 
t h e i r rat e o f change and are also involved in prolactin synthesis 
and possibly in regulating 'prolactin r e ceptors . Short term Ez 
treatment increases hypothalamic DA synthesis and turnover rate as 
well as DA concentration in portal blood. 33 However, administration 
of /j - estradiol acutely suppresses dopamine secretion into portal 
blood . 11 0 Es trogen may also antagonise the inhibitory action of 
dopamine on prolactin secretion by reducing the capacity of the 
lactotrope to incorporate dopamine into prolactin secretory 
g ranules. 81 It has also been postulated that Estrogen may directly 
a ff ec t the release of prolactin from rat lac tot rope cells in 
v i t r o. 82 
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In the human menstrual cycle, there is no clear cyclical 
prolactin secretion but oestrogen may be responsible 
i n c reased prolactin levels in the ovulatory and luteal 
change 
for 
in 
the 
phases as 
there is a positive correlation between prolactin and Ea at these 
times. 6 • 2 & 83 
Diet influences both prolactin and growth hormone relea s e in man. It 
appears to do so by an action of carbohydrate (high) and fat (low) 
on REM sleep. Nocturnal release of prolactin seems to be dependent 
on alternating REM and non - REM sleep and, by increasing the CHO and 
decreasing the fat in the diet, prolactin secretion is reduced. 94 
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Prolactin Releasing Factors and Suckling. 
A prolactin releasing factor has been well documented in birds 86 and 
has been postulated in mammals. 10 , a a • a • • a e • 8 7 TRH releases 
prolactin from prolactinoma cells in culture 88 in dissociated 
pituitary cell preparations 89 and in-vivo in certain conditions. 90 • 
91 TRH acts via membrane receptors and its uptake into prolactin 
cells seems to occur followed, possibly, by binding of 
to a nuclear component. 92 
the peptide 
Although TRH may be important in the suckling reflex it is uncertain 
whether this peptide plays a part in prolactin secretion under 
physiological conditions. 63 • 86 & 63 This controversy arises because 
most stimuli resulting in an elevated prolactin do not 
concommitantly result in an increase in TRH (and vise-versa) . 58 
However, suckling is associated with a concommltant rise of TRH and 
prolactin secretion in the rat. 7 • 1 0 • 3 8 Results of various 
investigations 10 point to the fact that the prime mediator of 
increase in prolactin responsiveness to TRH remains to be 
identified, but that one of these factors may be estradiol. 10 
Somatostatin may also modify the · TRH effect on prolactin 
secretion. 93 
At a cellular level, it has 
stimulates prolactin secretion 
bisphosphate (Ptd(4,5)Pz to 
been strongly suggested that TRH 
via hydrolysis of Phosphotydil 
Inositol triphosphate (Ins Pa) 
(possibly by directly stimulating phospholipase C) and thus 
increasing the intracellular calcium which, in turn, causes 
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, 
exocytosis of prolactin. 84 
effect on the intracelluar 
86 Alternatively, TRH may have a dual 
Ca++ pool - a rapid discharge and then a 
more sustained , slower onset via diacylglycerol accumulation and 
protein kinase C activation. 86 
Another re c eptor ligand stimulated intra c ellular process for 
prolactin may 
proteases. 87 
be arachadonic acid acting via c-AMP 86 and serine 
SUCKLING: 
A comprehensive review of this subject has been dealt with by 
numerous authors. 7 , 1 0 a. a a 
The neuroendocrine reflex induced by suckling gives rise to an 
acute, massive rise of prolactin. 63 The mechanism explaining this 
rise is speculative but may either be due to a i decrease in DA 
(PRH) 
or an 
increase in a stimulator (PRH) or both. 33 Stimulators which 
have been implicated include TRH 86 • 87 " 81 and VIP 33 but the data 
is inconclusive . aa, 88, 86, 80 , 88, 63 , 68 , 66 • 8 7 The evidence 
that this rise is due to a decrease in dopamine alone is also 
inconclusive 33 • 1 0 0 • l O l and the detailed physiological 
significance of dopamine dynamics occuring in conscious mothers 
during suckling has not been resolved . 10 
It has been 
decrease in 
suggested 
dopamine 
that the 
alone is 
brevity and magnitude 
not enough to account 
of this 
for the 
prolactin s urge during suckling . 88 The problem of interpretation is 
PAGE 18 
mad e ev e n more difficult by fact that other peptide 
neurotransmitters are released at 
the 
the same time and luteinizing 
hormone and follicle stimulating hormone are inhibited. 10 Thus the 
r elative importance of all these factors provide complexity which is 
difficult to interpret in isolation and may be the result of an 
i nteraction of all these different substances presumably acting via 
r eleasing factors from the hypothalamus. 
Two interdependent routes may govern prolactin secretion during 
s uckling. 33 One route includes the TIDA neurons, PRH and the long 
portal ves s els. The second involves the tuberohypophysial DA 
n eur ons , PRH and the short portal vessels. Prolactin and other 
modulators of prolactin s e c retion supposedly exert their major 
e ff ec t on t he hypothalamus long portal vessels. 33 The synchronous 
r el ea s e of prolac tin and oxytocin during suckling may be regulated 
i n the po s t e rio r pituitary but if this is so then prolactin activity 
wi ll have to be verified in this area . 33 
The phys iological role of serotonin in the suckling induced release 
of prolactin is well established, 38 • 1 0 0 , 3 4 , 86 , l O 1 Although 
s erotonin itself probably does not inq rease prolactin secretion, the 
neuronendocrine reflex which occurs in suckling acts via 
s erotoninergic pathways arising in the midbrain dorsal raphe nucleus 
· i n the hypothalamus. 3 3 • 3 4 The effects of serotonin may be modified 
by g o nadal s teroids . 33 It s timulates prolactin release probably via 
a PRH rel ease but may also involve dopaminergic and opiate 
me c h a n i sm s . 33 
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Thus, from this short review it is apparent that the control of 
prolactin secretion occurs at the level of the pituitary and the 
hypothalamus and that numerous hormone peptides and 
neurotransmitters, acting either on their own or in a complicated 
s ynergistic or antagonistic fashion with other factors, bring about 
an overall summation to effect final prolactin secretion and that 
yet other peptides may modulate this effect. There appears to be 
much controversy in elucidating which of 
particular relevance in the physiological 
dopamine restraint of prolactin secretion is of 
in this control. 
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these factors has 
in vivo situation but 
central importance 
PROJECT 
To investigate the role of GnRH in releasing synchronous spikes of 
LH and prolactin in t4e luteal phase of the menstrual cycle. A 
potent GnRH antagonist was administered to three women in the luteal 
phase of their menstrual cycle and the effect that this had on LH 
and prol~ctin secretion (and FSH) observed. Initially the dose 
response curve to the antagonist was established by administering 
incremental doses of the antagonist to a subject and finding the 
dose which would completely block LH secretion. Once this had been 
established, a supraphysiological dose of the antagonist was used in 
the subsequent experiments as described hereafter. 
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AIMS 
1. To establish the dose of a GnRH antagonist (Ac - D- Nal(2), 
D- CX - Me - 4-Cl - Phe 2 , D- Tryp 3 , D- Arg 6 , D- Ala 10 ), which would block 
GnRH release at the GnRH receptor site in the hypothalamus. This 
dose wa s then administered to three normally menstruating women 
in the luteal phase of the menstrual cycle and luteinizing 
hormone and prolactin responses were measured at approximately 
15 minute intervals over a period of 6-7 hours. 
2. To establish whether GnRH releases luteinizing hormone and 
prolactin from the anterior pituitary in the luteal phase of the 
menstrual cycle. 
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SUMMARY 
Methods Used 
Methods used to investigate the role of GnRH in the luteal phase of 
the menstrual cycle have focussed on either indirect means of 
observation or observation of hormone levels after the 
administration of GnRH. In the experimental design of the protocol 
which, follows, a potent GnRH antagonist was administered in the 
luteal phase and the effect on luteinizing hormone, prolactin and 
follicle stimulating hormone observed. The results obtained suggest 
the GnRH does not control the release of prolactin secretion as was 
formerly believed. 
Introduction 
It has been postulated that prolactin and luteinizing hormone share 
a common releasing factor, possibly GnRH (or 
~ 
LHRH) or that the 
mechanism producing synchronous spikes which occur in the luteal 
phase of the menstrual cycle related to a periodic 
tuberoinfundibular (TIDA) neuronal activity via 
dopaminergic mechanisms. GnRH may also act 
TIDA neuron activity 4 
indirectly 
decrease in 
inhibitory 
to modulate 
Braund et al 4 showed that there was a prolactin response to GnRH in 
the luteal phase and suggested that the observed synchrony in 
luteinizing hormone and prolactin secretion at this stage of the 
menstrual cycle was due to a physiological response of both the 
gonadotrope and the lactotrope cells to endogenous GnRH . 
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However, this was based on indirect evidence only. Using a potent 
GnRH antagonist, - D- Tryp 3 D-Arg 8 - synchronous luteinizing hormone 
and prolactin secretory spikes in the luteal phase of four normally 
menstruating women were analysed and the role of GnRH inferred from 
this method . 
The study initially focussed on the do s e of GnRH antagonist which 
would be sufficient to block luteinizing hormone (and perhaps also 
follicle stimulating hormone) from the pituitary gland and to 
observe any side effects which occurred on administration of this 
peptide . Onc e the blocking dose of the antagonist for luteinizing 
hormone was es tablished, the effect on prolactin s ecretion was 
observed during the luteal phase of the cycle. 
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Subjects, Materials and Method 
Four women with regular, normal menstrual cycles participated in a 
two day trial after signing informed consent. All had been quite 
healthy and were not taking any medication, including the oral 
contraceptive pill. None had a history of allergy or eczyma. Not all 
subjects were able to spend two consecutive days in hospital and 
thus the protocol allowed for blood samples for the basal levels of 
luteinizing hormone and prolactin to be taken in the luteal phase of 
o n e cycle and again after the antagonist had been administered 
during the luteal phase of the next menstrual cycle. Serum 
prog e sterone concentrations were assessed to check that the test was 
performed during the luteal phase. Although the subjects were not 
confined to bed rest, they were encouraged to rest as much as 
possible during the test. There was no prohibition on eating or 
drinking and although cigar~tte smoking was rlot proscribed it was 
discouraged for the period of the test. 
Subject 1 C.W. Age 42 years. 
Ai m: To a s sess the dose response curve. 
The test was performed on Day 18 of a . 30 day cycle. An intravenous 
cannula was inserted via the antecubital vein and was kept patent 
with a heparin - saline solution. 
·samples of blood were drawn at 20 minute intervals and sent for 
luteinizing hormone, prolactin, and follicle stimulating hormone. At 
time O minutes, 10,µg of the antagonist was given. This was repeated 
in incremental doses at 60 minutes, 120 minutes and 180 minutes and 
the doses given were 30,µg, lOQµg, and 3004g respectively. The serum 
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p r u g us ter o n e was <20 and i t i s ther efo r e un c ertain wh e ther the test 
wa s performed during the luteal phase. The test was repeated a month 
la t e r, u sing higher dos es of' the antagonist ( 300,µg, to 1000 ;£.g) and 
three and a half hour s later 10.;"g of (GnRH) was given to see whether 
there was any response or whether the blocking action of the 
antagonist was still apparent. This amount of GnRH was 
hourly intervals (three tim e s). 
repeated at 
Subject 2 ~ Age 24 years. 
On Day 18 of a 30 day cycle, blood was collected at 15 minute 
i ntervals for luteinizing hormone, folli cl e stimulating hormone and 
prolactin, for a total period of 6 hours, 45 minutes. A basal 
proge s terone level was taken. On the s ubsequent day, basal 
luteinizing hormon e , follicle stimulating hormone and p rola c tin were 
again c ollected for one hour and forty - five minutes at fifteen 
minute intervals. Thereafter, at time 0, 100,µg of the antagonist was 
~ 
given intravenously and 500.,ug boluses given at time 1 hour, 2 hours 
and 3 and a half hours. 
T h e results ar e tabulated below. 
Su bject 3 ~ Age 26 years. 
The test was performed during the luteal phase of one cycle to 
obtain basal levels and then repeated in the luteal phase of the 
s ub se quent me nstrual cycle after admin i stration of the antagonist as 
described for Su bjec t 2. Th e r es ults ar e tabulated below. 
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Sul:2ject 4 l:L__L_,_ Age 45 years. 
Basal levels were performed on Day 22 of a 28 day cycle. The 
antagonist was administered on Day 17 two cycles after the initial 
c y c le . A s imilar protocol as that for Subject~ (above) was used . 
The results are tabulated below. 
Materials: luteinizing hormone and follicle stimulating hormone 
were measured using Amersham RIA kits. The intra- assay coefficient 
of variation for luteinizing hormone was 3,7% for the low value (10 
mIU/ml) and 3,5% for the high value (59 . mlU/1) wi th 2,2% for 15 
mIU/1 and 2,8 % for 36 mlU/1 . The interassay ~ oefficient of 
v ariation wa s 8,1% for 10 mIU/1 , 4,3% for 15 mIU/1, 5 , 3% for 36 
mlU/1 and 6 , 2% for 59 mIU/1. 
The intra - assay coefficient of variation for folli c le stimulating 
hormone was 3,2% for the low value (5,9 mlU/mli) and 5% for the high 
• 
valu e (47 mIU/1) with 3,1% for 13 mIU/1 and 5,1 % for 25 mIU/1. The 
interassay coefficient of variation was 8,4% for 5,9 mIU/1, 5,4% for 
13 mlU/1, 5,1% for 25 mIU/1 and 10,3% for 47 mIU/1. 
The values for progesterone were: .- Intra - assay coefficient of 
variation: 8,4% for the low value (1,5 mIU/ml) and 5 , 8% for the high 
v alue (18 mIU/1) with 7,5% for 3,2mIU/l. 
Th e interass ay coefficient of variation was : 
10,0% for 8 , 4 mlU/1, 6 , 6% for 3,2m1U/l and 7,2 for 18mIU/l . 
The progest e rone was measured using a Diagnostic Products 
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Coat - a - count kit (RIA). 
Prolactin was measured using a Serono (RIA) kit. The in~rassay 
coefficient of variation was 6,2%. 
variation was not given . 
The intr«assay coefficient 
GnRH used for the dose response curve was Relifalt from Hoechst. 
of 
The GnRH antagonist was made in the protein synthesis peptide 
laboratory of the University of Cape Town, Medical School and had 
been tested for purity, allergic free properties and side effects. 
The antagonist has the chemical formula: 
Ac- D- Nal(2) ,D- (X-Me-4-Cl-Phe 2 , D- Tryp 3 , D- Arg 6 , D- Ala 10 
PAGE 28 
Results 
Subject 1 (Table 1 and Fig.l): Although incremental doses of the 
antagonist blocked luteinizing hormone secretion, there was less of 
a sustained effect on prolactin secretion. With higher doses of the 
antagonist (Table 2 and Fig.2) this effect was even more pronounced 
for LH but the effect on prolactin was minimal. Luteinizing hormone 
secretion is partially blocked after a dose of 300fag of the 
antagonist and completely inhibited after 500~. Prolactin and 
follicle stimulating hormone are not significantly affected. After 
1000 g of the antagonist was given at time 2 hours, the luteinizing 
hormone concentration remained suppressed for at least 1 hour. 
Subsequent administration of 10.,;Ug GnRH caused an increment in 
luteinizing hormone and prolactin. 
From this experiment it was established that 500.,/-g of the antagonist 
would block luteinizing hormone and that the effect would last for 1 
hour at least. It was also found that hourly boluses thereafter of 
500,fa,,g of the antagonist would also block luteinizing hormone 
release. 1000~ of the antagonist, i.e. twice maximum, was used in 
subsequent experiments to be su~e that maximum blocking or 
antagonism occurred. 
·Although the first set of values (Table 1) was associated with a low 
progesterone level (i.e. probably not in the luteal phase) it was 
felt that this would not affect the dose response curve of the 
antagonist on luteinizing hormone. 
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NAME AGE SEX LMP DRUG 
c.w. 24 years F Luteal Ant.6 
Sample Time Real Dose LH FSH PRL 
Number time (antagonist) 
1 -20 min 12 14.9 
2 0 lOug 8.6 12.3 
3 20 8. 1 10.7 
4 40 7.9 11. 9 
5 60 30ug 7.7 10.4 
6 80 9.7 9.8 
7 100 7.7 9.4 
8 120 lOOug 7.8 8.6 
9 140 7.2 7.3 
10 160 7.6 8.6 
11 180 300ug 5.8 8.9 
12 200 6.9 9.2 
13 220 6.8 9.3 
14 240 7.0 10.8 
15 260 6.4 9.3 
16 280 
17 300 5.9 10.7 
Table 1 
Dose-response values of antagonist action on LH and prolactin: 
Subject 1 
(LH in mIU/£ and prolactin in ng/£) 
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NAME AGE SEX LMP DRUG 
C.W. 24 F Luteal Antagonist 
LH - RH 
Sample Time Real Dose LH FSH PRL 
Number 8.2.85 Time 
1 -20" 9h40 7.8 12.2 7.8 
ant 
2 0 10h00 300ug 5.9 11. 6 6.3 
3 15" 10h15 7.2 11. 9 7.9 
4 30" 10h30 6.8 11. 4 6.9 
5 45" 10h45 5.5 10.3 5.6 
ant 
6 1 hour 11h00 500ug 2.6 10.4 7.9 
7 1'15" 11h15 1. 5 10.0 6.5 
8 1 I 30 11 11h30 1. 5 10.6 5.6 
9 1 I 45 II 11h45 1. 5 10.0 6.8 
ant 
10 2 hours 12h00 lOOOug 1. 5 10.7 8.2 
11 2 I 1 5 II 12h15 1. 5 9.5 6.3 
12 2'30" 12h30 1. 5 10.1 8. 1 
13 2'45" 12h45 1. 5 8.9 5.7 
14 3 hours 13h00 1. 5 8.6 7. 3 
15 3 I 1 5 II 13h15 1. 5 8.7 7.3 
LH-RH 
16 3'30" 13h30 lOug 1. 5 8.3 7.6 
17 3'45" 13h45 2.5 9.5 10.9 
18 4 hours 14h00 2.9 8. 9~ 10.7 
19 4 I 1 5 11 14h15 1. 5 9.5 11. 4 
LH-RH 1. 5 10.5 10.5 20 4'30" 14h30 lOug 
21 4'45" 14h45 5. 1 16.5 15.2 
22 5 hours 15h00 1. 8 11. 5 15.8 
23 5'15" 15h15 3.8 10.4 14.9 
24 5'30" 15h30 
LH-RH 
lOug 1. 5 10.6 5.3 
25 5'45" 15h45 ,8. 5 12. 1 18.0 
26 6 hours 16h00 9.1 10. 1 17.8 
27 6'15" 16h15 4.3 11.1 11. 8 
28 6'30" 16h30 1. 5 10.5 11. 5 
Table 2 
Dose - response values obtained for LH, FSH and prolactin 
after administration of the antagonist: Subject 1 
(LH and FSH in rnIU/£ and prolactin in ~g/m£) 
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Subject 2: The basal luteinizing hormone and prolactin levels 
showed synchronous peaks occurring at approximately time 0 
(beginning of the test) and lasting for fifteen minutes and another 
at time 6 hours 30 minutes lasting for more than fifteen minutes 
(see Table 3 and Fig.3 and 4). 
The GnnH antagonist appeared to block the initial peak of LH which 
occurred at minus 1 hour but did not seem to have any significant 
effect on prolactin or FSH peaks. (Table 4 and Fig 3 & 4) 
PAGE 34 
1iA!1E AGE .s.E.X. Ll1E. .D.R..U..G. 
SD 24 F now day 18 Antag. 6 
Sample Time Real Dose LH FSH PRL 
Number 11.3.85 Time (I.V.) 
1 09h30 0 8.9 5.5 7.4 
2 09h45 15min 6.3 4.7 7.6 
3 10h00 30min 7.0 5.0 6.5 
4 10h15 45min 6.0 4.8 6.3 
5 10h30 1hr 6. 1 . 4.79 6.4 
6 10h45 1'15" 4.7 4.4 7.5 
7 11h00 1 I 30 II 4.8 4.0 7. 3 
8 11h15 1 I 45 II 5. 1 4.2 8.7 
9 11h30 2hr 4. 1 4. 1 9.4 
10 11h45 2 I 1 5 II 4.2 3.7 8.6 
11 12h00 2'30" 3.8 4.4 6.0 
12 12h15 2'45" 3.5 3.4 7. 7 
13 12h30 3hr 3. 1 3.6 7.1 
14 12h45 3'15" 6.0 4.4 7.3 
15 13h00 3'30" 8.5 3.4 8.2 
16 13h15 3'45" 8. 1 3.4 11. 3 
1 7 13h30 4hr 6.0 4. 1 9.3 
18 13h45 4'15" 5.3 3.5 7.4 
19 14h00 4'30" 6.2 3.9 4.7 
20 14h15 4'45"· 5. 1 3.87 6.4 
21 14h30 5hr 4.0 3.5 9.5 
22 14h45 5 I 1 5 11 5.0 3.9 7.0 
23 15h00 5'30" 7.7 3. 1 8.7 
24 15h15 5'45" 5.4 3.3 9.5 
25 15h30 6hr 6.5 3. 1 9.3 
26 15h45 6'15" 3.5 3.8 i 8. 5 
27 16h00 6'30" 10.5 3.3 11. 6 
28 16h15 6'45" miss* 3.8 12.9 
*missing 
Progesterone 40.3 nMol/£ 
Table 3 
Basal measurements (values) of LH, prolactin and FSH in the 
luteal phase of the menstrual cycle: Subject 2 
(LH and FSH in mIU/£ and prolactin in ng/m£) 
Subject 2 : Graphs showing the effect of the GnRH antagonist 
on LH and FSH 
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NAME AGE SEX LMP DRUG 
SD 24 F day 19 Ant. 
Sample Time Real Dose LH FSH PRL 
Number 12.3.85 Time 
1 09h15 -1'45 11 2.9 3.6 7. 3 
2 09h30 -1'30" 3.4 3.3 7. 2 
3 09h45 -1' 15" 6.0 3.5 6. 1 
4 10h00 -1'00" 8.0 3.2 5.7 
5 10h15 -45" 11. 0 3.0 5.8 
6 10h30 -30" 9.6 3.5 6.8 
7 10h45 -15" 6.0 3.0 6.2 
8 11h00 0 lOOOug 6.2 3.2 4.4 
9 11h15 1 5 " 5.8 3.3 5.4 
10 11h30 30 11 4.6 3.0 5.9 
11 11h45 45 " . 4.9 3.4 4.9 
12 12h00 1 hour 500ug 3.4 3.4 5.0 
13 12h15 1 I 1 5 II 3.5 3.2 6.4 
14 12h30 1 I 30 II 4.6 3.2 6.4 
15 12h45 1 I 45 II 3.9 3.0 10.3 
16 13h00 2 hours 500ug 4. 1 2.2 8.4 
17 13h15 2 I 1 5 II 2.8 2.4 7. 2 
18 13h30 2'30" 3.3 2.3 8.5 
19 13h45 2'45" 3.6 2.9 8. 1 
22 14h30 3'30" 400ug 3.7 3.5 10.1 
23 14h45 3'45 11 3.6 2.8 8.4 
24 15h00 4 hours 2.2 2.9 7.3 
25 15h15 4 I 1 5 II 3. 1 2.4 8.4 
26 15h30 4'30 11 6.8 2.7 6.5 
27 15h45 4'45" 2.5 2.9 9.0 
28 16h00 5 hours 2.4 3.3 8.6 
29 16h15 5'15" 2.5 2. 7~ 7. 7 
Progesterone 60.8 nMol/£ 
Luteal phase: progesterone > 20 nMol/£ 
Table 4 
Serum LH, prolactin and FSH values in the luteal phase of the 
menstrual cycle after administration of the GnRH antagonist: 
Subj e ct 2 
(LH and FSH in mIU/£ and prolactin in ng/m£) 
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S ubjo c l 3: (Table 5 and Fig.5 & 6). Ba s al levels of the hormones 
showed synchronous peaks of luteinizing hormone peaks and prolactin 
occurring at time 0 and 2 hours 45 minutes. Th e re was also a 
luteinizing hormone peak which occurred at 6 hours 
thi s was not accompanied by a prolactin spike. 
30 minutes but 
After administration of the antagonist, luteinizing hormone peaks 
seemed to be suppressed but there appeared to be little effect on 
either prolactin or follicle stimulating hormone. (Table 6 and Fig.5 
& 6) 
'• 
PAGE 39 
NAME AGE SEX LMP 17/28 DRUG 
P.E. 26 years F Day 17 Nil 
Date: 21/5/85 
Sample Time Real Dose LH FSH PRL 
Number Time 
1 0 9h30 11. 8 7.2 8. 1 
2 15" 09h45 9.7 7 . 1 7.0 
3 30" 10h00 11. 5 7.5 5.4 
4 45" 10h15 8.4 7.4 4.9 
5 1 hour 10h30 8.0 7.5 4.9 
6 1'15" 10h45 8.4 6.9 5.4 
7 1 I 30 II 11h00 5.9 7 . 1 5.4 
8 1 I 45 II 11h15 7.8 7.8 4. 1 
9 2 hours 11h30 7.3 6.9 3 .9 
10 2'15" 11h45 5.3 6.8 4. 3 
1 1 2'30" 12h00 6.2 7.4 4.9 
1 2 2'45" 12h15 13.4 7. 5 13 .6 
13 3 hours 12h30 12. 8 7. 5 12. 1 
14 3'15" 12h45 10.3 7.2 10.1 
15 3'30" 13h00 7. 1 7.6 6.8 
16 3'45" 13h15 5.9 6.7 6. 3 
17 4 hours 13h30 5.4 6. 5' 5.7 
18 4'15" 13h45 5.2 6.2 5.4 
19 4'30" 14h00 4.5 6.2 6.2 
20 4'45" 14h15 5.4 6.4 5.2 
21 5 hours 14h30 5.4 5.9 5.0 
2 2 5'15" 14h45 3.1 6.2 4.7 
23 5'30" 15h00 3.6 7.0 5.3 
24 5'45" 15h15 3.7 5.8 5.8 
2 5 6 hours 15h30 4. 1 5.2 4.9 
26 6'15" 15h45 8.4 5.5 4.7 
2 7 6'30" 16h00 9.7 6.5 4.7 
28 6'45" 16h15 9.2 5.8 4. 8 
Progesterone 46.8 nMol/.e 
Table 5 
Basal measurements (values) of LH, prolactin and FSH in the 
l u teal ph a se o f the menstrual cycle: Subje c t 3 
(LH and FSH in mIU/.e and prolactin in ng/m.e) 
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NAME AGE SEX LMP 18/28 DRUG 
Date: 11/7/85 26 years F Antag.27 
P.E. 
Sample Time Real Dose LH FSH PRL 
Number Time 
1 -2 hours 09h30 11. 7 9.2 13.4 
2 -1'45 11 09h45 9 .1 8.2 10.3 
3 -1'30 11 10h00 8.0 8.1 8.9 
4 -1'15 11 10h15 9.3 9.4 8.7 
5 -1 hour 10h30 7.6 8.2 6. 1 
6 -45 11 10h45 4.4 8.3 6.4 
7 -30" 11h00 3.9 7.7 5.8 
8 -15-" 11h15 5.2 8.9 6.8 
9 0 11h30 lOOOug 5.7 8.0 7. 1 
10 1 5 " 11h45 3.3 7.9 5.9 
11 30" 12h00 3 .0 8.1 7. 1 
12 45 II 12h15 3.4 8.5 13.4 
13 60 II 12h30 
14 1'15" 12h45 500ug 2.8 8.0 8.3 
15 1 I 30 11 13h00 4.3 8.7 7.8 
16 1 I 45 II 13h15 5.5 7 . 't 5.8 
17 2 hours 13h30 2.7 7.2 5.8 
18 2 I 15 II 13h45 500ug 3.4 8.0 6.3 
19 2'30" 14h00 2.8 7.2 5.6 
20 2'45" 14h15 2.7 8.3 5. 1 
21 3 hours 14h30 500ug 4.8 7.9 5.0 
22 3 I 1 5 II 14h45 2.7 7.4 6. 1 
23 3'30" 15h00 . 3. 1 7.7 6.6 
24 3'45" 15h15 3.4 7.4 7. 1 
25 4 hours 15h30 500ug 4.6 8.3 6. 2 
26 4 I 1 5 II 15h45 3.1 7.3 4.8 
27 4'45" 16h15 4.2 8.2 6 . 2 
28 5 hours 16h30 3.0 7.8 5 .8 
Progesterone 74.6 nMol/£ 
Table 6 
Serum LH, prolactin and FSH values in the luteal phase of the 
menstrual cycle after administration of the GnRH antagonist: 
Subject 3 
(LH and FSH in mIU/e and prol acti n i n t g /m£) 
-E 
-:) 8 
e 
-
/ J: CJ) 4 
/ ~ / 
0 
12 
-E 
-0 C: 8 
-
...J 
a: 
Q. 
4 
0 
Subject 3 Graphs showing the effect of the 
L 
GnRH antagonist on FSH and prolactin 
flG 6 
P.E. 21.5.'85, 11.7.'85 
ANTAG. @ 1 OOOµg 500µg 500µg 500µg 500µg 
J J J J I After 
, /"'· A . ,,,. antag. 
·-· '-·-. ,,· ""·-·- -·-· ' /·, /·, ·"..! 
.. 
-2 -1 
~ ___....._ ·-./"'·..,· ·, ...... ·-· ./ -
0 1 2 3 4 
TIME (hr) 
·.· 
After 
antag 
. I 
.····· 
' Basal 
5 
Subject 4: (Table 7 and Fig.7 & 8) The peaks occurred in the basal 
period at time 1 hour 45 minutes and probably at time 6 hours and 15 
minutes and the second peak was associated with a prolactin spike. 
During the second part of the experiment using the antagonist (Table 
8 and Fig.? & 8) a luteinizing hormone peak occurred at the 
beginning of the sampling period (Not accompanied by a prolactin 
peak): The antagonist blocked the luteinizing hormone secretion most 
noticeably at time 3 hours and 4 hours but does not appear to have 
suppressed prolactin secretion or 
secretion. 
PAGE 44 
follicle stimulating hormone 
NAME AGE SEX LMP 22/28 DRUG 
H.L. 45 years F Ant. 27 
Date 22.8.85 
Sample Time Real Dose LH FSH PRL 
Number Time 
1 0 09h30 10.6 11. 4 8.1 
2 1 5 " 09h45 8.9 10.5 6.9 
3 30" 10h00 8.9 10.7 7.5 
4 45" 10h15 7.6 9.9 6.3 
5 1 hour 10h30 7.6 8.2 5.3 
6 1 ' 1 5 " 10h45 9.7 9.8 9.8 
7 1 '30" 11 hOO · 9. 1 8.8 6.0 
8 1 '45" 11h15 17.8 10.9 7.8 
9 2 hours 11h30 18. 1 10.8 6.4 
10 2'15" 11h45 15.7 10.0 8.3 
11 2'30" 12h00 11. 9 10.0 9.7 
12 2'45" 12h15 12.8 10.7 9 . 8 
13 3 hours 12h30 7.9 10.5 9.3 
14 3'15" 12h45 8.5 10.9 8.4 
15 3' 30 " 13h00 7.3 11. 0 8.0 
16 3'45" 13h15 6.0 9.9 8.0 
17 4 hours 1'3h30 7.4 10 .() 8.3 
18 4'15" 13h45 6.0 9.0 8.8 
19 4'30" 14h00 5.4 8.8 8.6 
20 4'45" 14h15 8.3 9.6 9.8 
21 5 hours 14h30 7.7 10.4 9.3 
22 5 ' 1 5 " 14h45 6.9 9.3 8.6 
23 5'30" 15h00 4.6 8.0 8.3 
24 5'45" 15h15 3.5 8.6 8.6 
25 6 hours 15h30 5.7 9.0 9 .9 
26 6'15" 15h45 11. 9 9.6 12. 2 
27 6'30" 16h00 14.3 10.5 13. 1 
28 6'45" 16h15 9.7 10.0 13.7 
29 7 hours 16h30 9 .1 9.1 14.8 
Progesterone 32 .7 nMol/£ 
Table 7 
Basal measurements (values) of LH, prolactin and FSH in the 
luteal phase of the menstrual cycle: Subject 4 
(LH and FSH in mIU/£ and prolactin in ng/m£) 
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Subject 4 Graphs sh.owing the effect of the GnRH 
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NAME AGE SEX LMP 17/28 DRUG 
H.L. 45 years F 
Date: 19.12.85 
Sample Time Real Dose LH FSH PRL 
Number Time 
1 -2 hours 09h00 13.7 11. 0 9.7 
2 -1'45" 09h15 11. 8 10.5 8.7 
3 -1'30" 09h30 10.6 10.8 8.5 
4 - 1 ' 1 5 " 09h45 8.7 10.7 8.5 
5 -1 hour 10h00 9.3 11.1 7.6 
6 -45" 10h15 10. 1 10. 1 6.9 
7 -30" 10h30 8.4 9.7 7. 9 
8 -15" 10h45 8.5 10.4 7.5 
9 0 11h00 lOOOug 6.8 10.3 7.3 
10 1 5 " 11h15 6.5 10.5 7 . 1 
11 30" 11h30 7.8 9.7 7.4 
12 45" 11h45 6.4 9.3 7.9 
13 1 hour 12h00 500ug 7.4 9.4 8.7 
14 1 ' 1 5 " 12h15 5.9 9.8 8.5 
15 1 '30" 12h30 5.6 9.4 8;2 
16 1'45" 12h45 5 .6 9.h 8.7 
17 2 hours 13h00 500ug 5.7 8.9 8.8 
18 2 ' 1 5 " 13h15 4.6 8.9 8.9 
19 2'30" 13h30 5.7 9.5 10.2 
20 2'45" 13h45 4. 1 8.9 10.6 
21 3 hours 14h00 500ug 3.0 9.0 10.3 
22 3'15" 14h15 5. 1 8.4 10.0 
23 3'30" 14h30 5.2 8.7 9.9 
24 3'45" 14h45 2. 7 7.3 8 . 9 
25 4 hours 15h00 500ug 2. 7 7.7 8.8 
26 4'15" 15h15 3.0 8.3 8 . 3 
27 4'30" 15h30 4.8 7.5 8.2 
28 4'45" 15h45 3.4 7.0 8.3 
29 5 hours 16h00 5 . 0 7.6 9.7 
Progesterone 51.1 nMol/R, 
Table 8 
Serum LH, prolactin and FSH values in the luteal phase of the 
menstrual cycle after administration of the GnRH antagonist: 
Subject 4 
(LH a nd FSH in mIU/R, and prolactin in ng/me) 
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5 
STATISTICS 
Tables 9, 10 and 11 and figures 9, 10 and 11 depict the mean basal 
and experimental values (i.e. after administration of antagonist) 
for LH, FSH and prolactin. The serum concentrations of the 
respective hormones are given on the x-axis and the number of the 
specimen (i.e. time) on the y - axis. Tables 9, 10 and 11 also show 
the means and standard error of the means for all the specimens 
taken . over the test period, both basal and after administration of 
the antagonist. Although there may be limitation in this method by 
averaging the values of peak hormone secretion occuring at different 
times for different subjects, thus giving occasional unacceptably 
high standard deviations and SEM values, the overall pattern for LH 
is still one of a blocking effect by the antagonist which is not 
evident in Figure 11 for prolactin (see Table 1 1 ) secretion. (Two 
ways of overcoming this limitation would have been to start all the 
tests for each case at time O with a peak or else to shift all peaks 
~ 
occurring in the course of the test period across so that they 
coincided . The mean values could then have been confidently 
determined. The method adopted in the above protocol is acceptable 
if peaks occur close to one another providing the duration of the 
peaks were not too long. The means became more inaccurate as peaks 
occurred further apart.) 
Successive maximums and minimums were located on each curve (Fig. 9 
to 11) and differences between these means tested using the t-test. 
The significance of these peak-trough sets were found to be between 
p< 0,01 and f< 0,1 for LH (basal). After the administration of the 
antagonist there were no significant peak-trough differences for LH 
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i. e . flat curve. This response differed markedly when compared with 
FSH and prolactin. There were no significant peak- trough sets for 
FS H either before or after the administration of the antagonist. 
P rolactin showed significant and consistent peak-trough sets both 
before and after the administration of the antagonist ( P = 0, 8 top= 
0, 05) . 
Th e t - test was used to determine peaks as it uncovered more 
sign if icant s pikes of secretion during the test period that did the 
3 CV method. The statistical analysis used was similar to that used 
by othe r authors. 104 
P ul se anal y sis is critical in interpr e ting the synchronicity of 
pr ol a ctin and luteinizing hormone. Two methods commonly employed are 
t h e "t - test" and the 3 CV approach . The former is probably more 
samples are obtained as val i d when multiple, freque~t 
fe wer false pos i tive peaks: this is true if samples are 
it yields 
taken at 
e . g. 5 minute intervals. 104 When the sampling interval is reduced 
f r o m 20 minutes to 5 minutes th~re is a modest increase (50 7 5%) 
i n luteinizing hormone and follicle stimulating hormone peak 
fre qu e n c y u si ng the t-te s t. However, using the 3 CV method, 
l ut einizing hormon e peak frequency 
s timulati n g h or mon e frequency by 67%. 
inc reased by 8 2% and follicle 
Beca u s e the r e were so few peaks whi c h occurred wi t h 15 minute 
sampling p e riods during the cours e of the test per i od in the cases 
abov e, the mo re s tatistically significa nt peaks were un c overed using 
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the "t" test rather than the 3 CV method. The t-test may also be 
advantageous in indicating the greatest difference between the peak 
frequency in the patients and that in the noise series. 104 This test 
also has the advantage of using the actual variance at the nadirs 
and peaks, rather than a predicted variance calculated from the mean 
intra assay CV of the assay. 104 One other advantage of this method 
is that it offers an estimate of the likelihood of false positive 
(type· 1) errors. Had we increased our sampling times to 5 minute 
intervals this may well have resulted in a 50 - 75% increase in peak 
frequency using the t-test method i .e . smaller peaks would have been 
included as statistically important because the samples would have 
been obtained nearer the peaks and nadirs. 104 More frequent sampling 
at e.g. 4 minutes or less would have uncovered (more) high frequency 
low amplitud e spikes but probably not high amptitude peaks . 106 
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Discussion 
F r om the data pres e nted above it seems that a supramaximal dose of a 
p o t e nt GnRH antagonist which was able to block luteinizing hormone 
was not able to block synchronously occuring prolactin secretory 
p e aks in the luteal phase of the menstrual cycle. Another 
observation was that the antagonist appeared to have very little 
effect on FSH secretion during this phase of the menstrual cycle. 
The lut e al phase of the menstrual cycle is typified by a low basal 
r ate of lut e ini z ing hormone secretion punc tuated by e pisodic pulses 
precise of substantial magnitude . and was used to allow more 
c har ac terization of pulse analysis and reduce the probability of 
a ssociating a prolactin pulse with a random fluctuation of the 
l uteinizing hormone assay. 4 Prolactin pulse s are also s ignificantly 
higher in the luteal phase. 6 • 1 ., 
Ther e is concordance of LH, FSH and prolactin secretory spikes 
during the luteal phase 83 • 4 but the reason for this is unknown. 4 
One postulate was that gonadal steroids possibly modulated LH 
1 0 8 1 0 9 Both oestrogen 83 • 1 1 0 , l 1 1 • 1 1 2 and pul s es. 107 • 
pr o g e sterone acting either on its own 113 or synergistically with 
oes trogen 114 may enhance prolactin secr e tion by possibly modulating 
t he a c tion of dopamine at the la c totrope initially by increasing 
i nhibition v i a DA and then as a rebound, i n c reasing prolactin levels 
i ts e lf aft er DA withdrawal. 116 This may involve estradiol indirectly 
i nhib it ing d opamine by increasing the r e ceptor sen s i t iv i ty of the 
lac t o t r o p e to exo g enous DA 116 • 80 or by directly mo dulating DA at 
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the la c totrope receptor. 1 1 7 8 0 It may also stimulate the 
l t1 c totrope directly to relea s e prolu c tin . 118 Est rt1diol affects the 
numbers of GnRH receptors, 119 the size of the releasable pool of 
luteinizing hormone and the phasic r el eas e of GnRH. 110 However, it 
s hould be noted that the admini s tration of oestrogen and 
progesterone to women with chronic hypothalamic anovulation does not 
release either LH or prolactin (and thus probably not via GnRH 
directly). 4 
It 1s thus apparent that the interplay of estradiol and dopamine on 
the lactotrope and gonadotrope acting either directly or indirectly 
via dopamine or GnRH secretion is complex . 
Braund e t al po s tulated that GnRH itself was able to increase the 
secretion of both hormones from the pituitary gland 4 as synchrony of 
LH and prolactin was retained during naxolone infusion and after the 
' 
injection of GnRH, and was abolished by administration of the 
dopamine receptor antagonist metochlopramide. 4 In subject 1 above, 
GnRH appeared to stimulate both prolactin and LH which would be in 
keeping Braund's (et al) observation. 4 These authors felt that it 
was unlikely that periodic reduction of TIDA neuron activity 
accounted for LH and prolactin synchrony because MCP treatment 
abolished the prolactin but not the LH pulsality. 4 However, it is 
·possible that GnRH itself may inhibit the activity of TIDA neurons 
which may 1 n turn aff ec t LH and prola c tin pulses in a synchronous 
manner. (However , this association may hav e been fortui taus as the 
long durat ion of this peak is perhap s a ga inst i t being due to a 
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s pontaneou s physiological peak.) 
Conclusion 
From this data a potent GnRH antagoni s t appears not to have blocked 
prolactin peaks or FSH su·rges. It therefore seems unlikely that GnRH 
i s solely responsible for the synchronous secr e tion of LH and 
prolactin. An interesting observation was that the GnRH antagonist 
also failed to suppress FSH secretion. 
This pilot study had the limitation of using a small number of 
subjects in the sample group and further testing using more subjects 
and employing more frequent blood samples at shorter time intervals 
betw e en s amples would help to validate the the above 1·e sults. 
T h e GnRH antagonists have thus provided a promising and useful tool 
for investigating the physiology of the menstrual cycle . 
. 
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